Acute myeloid leukemia with intermediate cytogenetic risk (ICR-AML) needs to be stratified. The abnormal gene expression might be prognostic, and its cutoff value for patient grouping is pivotal.
Background
Acute myeloid leukemia (AML) is a heterogeneous disease, and cytogenetic analysis is the classical method and framework for stratification [1] [2] [3] . Nearly half of AML patients are defined as an intermediate cytogenetic risk group, but their outcomes greatly varied [1] [2] [3] . Therefore, further stratification is needed to guide appropriate treatment. Over the past 2 decades, dozens of gene mutations have been discovered in AML, and the characterization of their prognostic impact is ongoing [4] [5] [6] .
Apart from gene mutation, abnormal gene expression might also be prognostic [7, 8] , and Ecotropic viral integration site 1 (EVI1), WT1, and MLL partial tandem duplications (MLL-PTD) are representatives [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The EVI1 gene is located on human chromosome 3q26 and encodes a transcription factor essential for both normal and malignant hematopoiesis [23] . It was shown that EVI1 was aberrantly highly expressed in AML patients, both with and without cytogenetic abnormalities 3q26 [24, 25] . In the past decade, several studies have demonstrated an adverse prognostic role of EVI1 in adult AML and AML patients with intermediate cytogenetic risk (ICR-AML) [9] [10] [11] [12] [13] [14] , but its effects on complete remission (CR) achievement were contradictory [10, 11, 13] . To date, almost all such studies have been undertaken in European populations and its prognostic significance in other populations needs to be evaluated. In addition, the EVI1 cutoff value for patient grouping remains obscure.
The cutoff value is the key to defining abnormal expression and differentiating patients. An abnormally-expressed gene is typically expressed in normal hematopoietic cells but with different levels from those found with leukemia [26] [27] [28] . As for the determination of EVI1 high expression, some used the upper limit in normal bone marrow (NBM) as the cutoff value [13] , whereas others arbitrarily selected from several values [9] [10] [11] [12] . Therefore, the optimal threshold for clinical practice remains a challenge.
In the present study, by measuring EVI1 expression as well as additional molecular abnormalities in 191 consecutive adult ICR-AML patients receiving chemotherapy at our institute, we compared different cutoff values and evaluated their prognostic effects on outcomes.
Material and Methods

Patients and treatment
A total of 191 adult ICR-AML patients were enrolled in the present study. These patients were consecutively diagnosed from January 2009 to December 2015, had available cytogenetic results, received at least 2 cycles of chemotherapy, were followed up at our institute, and did not receive allogeneic hematopoietic stem cell transplantation (allo-HSCT). Furthermore, all patients had available RNA and DNA extracted from bone marrow samples at diagnosis. The definition of cytogenetic risk was based on NCCN guidelines [29] . Intermediate-risk cytogenetics included normal cytogenetics, +8 alone, t(9;11), and other abnormalities not classified as favorable or unfavorable. The analyzed patients included 148 (77.5%) patients with normal karyotypes and 1 (0.5%) patient with t(9;11)(p22;q23). The basic characteristics are shown in Table 1 . In addition, a total of 27 NBM samples were aspirated from normal volunteers who were allo-HSCT donors and we extracted RNA.
All patients received idarubicin (8-10 mg/m 2 ) for 3 days in combination with cytarabine (100 mg/m 2 ) for 7 days as the first induction regimen. Patients who achieved partial remission repeated the first induction regimen, and those who had no response were treated with other regimens. The consolidation therapy included 4 cycles of high-dose cytarabine (2 g/m 2 , q12h, 3 days) followed by 2 cycles of regimens containing cytarabine and anthracyclines. The cutoff date for follow-up was September 20, 2016 . This study was approved by the Ethics Committee of Peking University People's Hospital. All patients and volunteers provided written informed consent in accordance with the Declaration of Helsinki to participate in the present study.
Polymerase chain reaction (PCR)
Nucleated cells were obtained by treating fresh bone marrow samples with 0.144 M NH4Cl, 0.01 M NH4HCO3 to lyse the red cells. Total RNA and genomic DNA were individually extracted from bone marrow nucleated cells using Trizol and DNAzol Reagent (Invitrogen, Carlsbad, CA, USA). RNA was used to test EVI1, MLL-PTD, and WT1 transcript levels by TaqMan-based real-time quantitative PCR (RQ-PCR), and DNA was used to amplify FLT3-ITD (internal tandem duplication) by qualitative PCR and NPM1 mutations (A, B, and D type) by TaqMan-based RQ-PCR [30] . RQ-PCR was performed with a ABI PRISM 7500 Sequence Detector (Applied Biosystems, Foster City, USA). The primers and probes for the EVI1 transcript were designed using Primer Express Software (Applied Biosystems, Foster City, USA) to detect all subtypes (1a, 1b, 1c, 1d, and 3L), and the sequences were as follows: Forward primer: 5'-CCCATGTGCCAGAGGAACTT-3' (in exon 14) Reverse primer: 5'-CAGTGACAGCATCATAGCATATGC-3' (in exon 15) Probe: 5'-FAM-CAGCCGTTACACAGAAAGTCCAAATCGC-TAMRA-3' (in exon 14)
The MLL primers and probes annealed to locations in exons 8-10 and 3 of the MLL gene to detect fusion between exons 8-10 and exon 3. The WT1 primers and probe have been previously reported [31] . ABL was used as a control gene, and the corresponding primers and probe were based on a report from the Europe Against Cancer Program [32] . The EVI1, MLL-PTD, and WT1 transcript levels were calculated as the percentage of target transcript copies/ABL copies.
Statistical analysis and definitions
Pairwise comparisons of the variables between groups were performed using the Mann-Whitney U test for continuous variables and Fisher's exact test for categorical variables. A receiver operating characteristic (ROC) curve was used to identify optimal cutoff levels that best discriminated patients with different responses (achieving CR) and outcomes (relapse). Survival functions were estimated using the Kaplan-Meier method and compared using the log-rank test. Relapse-free survival (RFS) and disease-free survival (DFS) were measured from the date when CR was achieved. The events were relapse for RFS and death during CR1 or relapse for DFS. The event for overall survival (OS) was death (regardless of the cause), and patients were queried at the date of last follow-up to determine whether they were still alive, or were censored on the date they were last known to be alive. Variables associated with P<0.20 in the univariate analysis were entered in multivariable analysis performed by the Cox models. The level for a statistically significant difference was set at P<0.05 for all univariate tests. The SPSS 13.0 software package (SPSS Inc., Chicago, IL), and GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA) were used for data analysis.
Results
Patient outcomes
The median follow-up time for the entire cohort was 13 (2- 
Determination of optimal cutoff values of EVI1, MLL-PTD, and WT1
The ROC curves showed that EVI1 transcript levels significantly differentiated patients in relapse (area under curve 0.59, P=0.049, Figure 2A ). A value of 1.0% (a 0.9-log reduction from the upper limit in NBM) was identified as the optimal cutoff value based on its maximal Youden index (0.20) among all values. Therefore, EVI1 ³1.0% and <1.0% were defined as high expression and low expression, respectively. In the entire cohort, 23 (12.0%) patients had high EVI1 expression (³1.0%). In addition, EVI1 transcript levels did not significantly differentiate patients in CR achievement after 1 and 2 courses of induction (P=0.16 and 0.42).
Similarly, both MLL-PTD and WT1 significantly differentiated patients achieving CR after 2 courses of induction ( Figure 2B , 2C, P=0.023 and 0.041) but not in relapse (P=0.58 and 0.16), and the optimal cutoff value was 1.0% and 10.0%, respectively. In the entire cohort, 16 (8.4%) and 123 (64.4%) patients individually had high MLL-PTD and WT1 expression, respectively (³1.0% and 10.0%).
Relationship between EVI1 expression and other patient characteristics and molecular abnormalities at diagnosis As shown in Table 1 , high EVI1 expression (³1.0%) was significantly related to low hemoglobin levels, low blast percentage in bone marrow, and high WT1 expression (all P<0.05) but not age, sex, white blood cell (WBC) or platelet counts, FLT3-ITD frequency, NPM1 mutation frequency, and FAB subtype. Furthermore, EVI1 expression was not relevant to the distribution of FLT3-ITD (-)/NPM1 mutation (+) (P=0.80).
Effects of EVI1 expression and other molecular abnormalities on CR achievement
The CR rates after 1 and 2 courses of induction in the entire cohort were 65.4% (125/191) and 83.2% (159/191), respectively. As shown in Table 2 , EVI1 grouped by 1.0% had no impact on CR achievement (all P>0.05). Similarly, WT1 expression did not affect CR achievement. Differing from them, both high MLL-PTD expression and NPM1 mutation (+) were significantly related to lower 1-course and 2-course induction CR rate ( Figure 3D -3F). (n=150) 14.9%), respectively. The NPM1 mutation had no impact on the RFS rate in FLT3-ITD (-) patients (P=0.53), whereas EVI1 ³1.0% was significantly related to a higher 2-year RFS rate in both the NPM1 mutation (-) and (+) patients (P<0.0001 and P=0.0079, Figure 4B ). A-C showed the impacts in the entire cohort (n=191), and D-F showed the impacts in patients with normal karyotypes (n=148).
FLT3-ITD (-) patients
763
Indexed The effects of variables associated with P<0.20 in univariate analysis were analyzed by multivariable analysis. As shown in Table 4 , both high EVI1 expression (³1.0%) and FLT3-ITD (+) were independent adverse prognostic factors for RFS, DFS, and OS in the entire cohort. Furthermore, PLT count <100×10 9 /L was an independent adverse prognostic factor for RFS and DFS, and BM blast >65% was an independent adverse prognostic factor for RFS.
Comparison between ROC curve and the upper limit of NBM-determined cutoff value
To further evaluate the impacts of EVI1 expression on relapse and MLL-PTD expression on CR achievement, the patients were individually classified into 3 groups according to the ROC curve, and the upper limit of NBM-determined cutoff values. Patients with EVI1 levels between 1.0% and 8.0% had 2-year RFS rates similar to those with EVI1 ³8.0% (P=0.16, Figure 5A ), and both patient groups had significantly lower 2-year RFS rates than those with EVI1 <1.0% (P=0.0005 and 0.027, Figure 5A ). Furthermore, the 1-and 2-course induction CR rates of patients with MLL-PTD levels between 0.08% and 1.0% were similar to those with MLL-PTD <0.08% (P=0.80 and 0.28, Figure 5B ), and they were all significantly higher than those of patients with MLL-PTD ³1.0% (All P<0.05, Figure 5B ).
Discussion
AML patients with intermediate cytogenetic risk need to be differentiated [1] [2] [3] [4] . In the present study, EVI1 expression was evaluated in combination with other molecular abnormalities in adult ICR-AML patients who received chemotherapy only. We found that the ROC curve-determined high EVI1 expression was an independent poor prognostic factor for relapse and survival in ICR-AML patients, patients with normal karyotypes, and FLT3-ITD(-) patients.
Many genes involved in leukemogenesis are expressed in both leukemic cells and normal hematopoietic stem cells/progenitors (e.g., EVI1, WT1, and MLL-PTD) [26] [27] [28] . The abnormal expression of some genes (e.g., WT1) has been widely used to monitor minimal residual disease (MRD), in which the upper limit of NBM expression was usually used to define overexpression [33] . Another role of gene overexpression is prognosis. To best differentiate patients, determining the optimal cutoff value is important. Notably, the optimal cutoff value for prognosis may not always be the same as the upper limit in NBM. For example, we recently reported that WT1 £5.0% (approximately 1-log increase compared with the upper limit in NBM) at diagnosis was significantly related to poor outcomes in t(8;21) AML patients [17] . In the present study, we demonstrated that a value less than the normal upper limit was the optimal cutoff value for EVI1 with the largest Youden index. Comparisons revealed that the ROC curve analysis-determined cutoff value, but not the upper limit in NBM, significantly differentiated patients with respect to relapse. It was the same for MLL-PTD levels to differentiate patients in CR achievement. Therefore, the optimal prognostic cutoff value for abnormally-expressed genes needs to be identified by patient outcome data. 
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individually showed that EVI1 (+) AML patients had significantly lower induction CR rates than EVI1 (-) AML patients [10, 11] , but Haas et al. did not observe this association [13] . With respect to ICR-AML, Groschel et al. reported that the CR rate was not related to EVI1 expression [11] . Similarly, our results showed that EVI1 transcript levels had no effect on CR achievement.
Almost all relevant studies have shown an adverse impact of high EVI1 expression on outcomes in AML, despite considering different end points. High EVI1 expression was demonstrated to independently predict event-free survival (EFS), DFS, RFS, and OS [9] [10] [11] 13] . As for ICR-AML, EVI1 high expression was shown to predict EFS, RFS, and OS by univariable or multivariable survival analysis [9] [10] [11] [12] [13] [14] . In the present study, we confirmed the strong poor prognostic impact of EVI1 overexpression in the Chinese cohort. Therefore, high EVI1 expression strongly predicts poor outcomes for both AML and ICR-AML, which suggests its possible role in patient stratification in clinical routine. 
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In the AML cohort, Groschel et al. reported that EVI1 (+) was inversely correlated with both FLT3-ITD (+) and NPM1 mutation (+) [11] . However, in the present study, no significant correlations were observed. Furthermore, FLT3-ITD (-)/NPM1 mutation (+) patients were demonstrated to have better outcomes and were defined as favorable risk [29, 34] . In the present study, NPM1 mutation was not found to be prognostic in FLT3-ITD (-) patients. These findings might be caused by the exclusion of patients receiving allo-HSCT. In this study, we found that high EVI1 expression was associated with a lower RFS rate in both NPM1 mutation (-) and (+) patients without FLT3-ITD. Therefore, EVI1 expression may further stratify FLT3-ITD (-) patients receiving chemotherapy, regardless of NPM1 mutation.
Although almost all relevant studies have shown an adverse impact of EVI1 high expression on outcome in AML, it was difficult to make direct comparisons among them, which hinders the direct application of EVI1 expression testing in clinical practice. In addition to the cutoff value selection method, differences also existed in the detection method and control gene for normalization. In the early studies, each subtype of EVI1 was individually tested and analyzed. Subsequently, the common site of all subtypes was amplified and quantitated. Both absolute and relative real-time quantitative PCR methods were used [9] [10] [11] [12] [13] . Gene expression profiling (GEP) was also used [14] . The control gene used included PBGD, cyclophilin, ubiquitin C, G6PD, and GUSB [9] [10] [11] [12] [13] . Thus, standardization of the EVI1 transcript testing and reporting is required. In the present study, we selected ABL as a control gene and the EVI1 transcript level was expressed as a percentage of EVI1 to ABL copies, a widely used quantitation method for other fusion genes in hematologic malignancies [32] .
MLL-PTD and WT1 expression were simultaneously assessed in the present study. In contrast to previous reports [18] [19] [20] [21] [22] 35] , high MLL-PTD expression was shown to be significantly associated with a low CR achievement rate. For outcomes, the reported impact of MLL-PTD was discordant [18] [19] [20] [21] [22] 35] . In the present study, MLL-PTD (+) was not found to be relevant to relapse and survival in ICR-AML. The therapy composition, drug dose, and race all might affect CR achievement. In addition, differences in the cutoff values for defining MLL-PTD (+) might also affect its prognostic role. The impact of WT1 expression on outcomes in AML remains controversial [15] [16] [17] . WT1 expression was not prognostic in ICR-AML in the present study. This inconsistency indicates that the prognostic value of WT1 expression is weak and is affected by other factors, such as AML subtype and treatment modality.
The included variables affected the multivariate analysis results. Great progress has been made in the discovery of prognostic gene mutations in AML in the past 2 decades [6] . The limitation of this study is that it was a retrospective study. Although we investigated the widely used overexpression markers WT1, MLL-PTD, and FLT3-ITD, we did not screen CEBPA, DNMT3A, and other newly identified mutations.
Conclusions
EVI1 expression at diagnosis could further stratify ICR-AML, and high EVI1 expression predicted poor outcomes in patients receiving chemotherapy. EVI1 transcript levels should be routinely assessed at diagnosis for stratification once a standard laboratory protocol is established and the cutoff value is determined. Furthermore, the impact of EVI1 expression should be fully investigated in the context of all newly identified gene mutations in AML.
